Global Cancer Antibody Drug Conjugates Market & Clinical Pipeline Insight 2022
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
“Global Cancer Antibody Drug Conjugates Market & Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical parameters involved in the development of global cancer antibody drug conjugate market. In recent years antibody drug conjugates have emerged as new growth frontier for the companies involved in the research and development of drugs for the treatment of cancer. As per report findings, currently there are 243 antibody drug conjugates in clinical pipeline for the treatment of cancer. Majority of antibody drug conjugates for the treatment of cancer are in preclinical stage followed by research phase clinical trials. There are 6 cancer antibody drug conjugates commercially available in the market. Report helps to analyze the clinical pipeline of antibody drug conjugates by Company, Indication, Mode of Action, Formulation & Phase.
Antibody drug conjugates have emerged as new addition to the cancer therapeutic segment which is already overcrowded and consists of numerous competitors. Antibody drug conjugates are based on monoclonal antibodies which delivers drugs in highly targeted manner. Their superior pharmacological profiles have allowed the pharmaceutical companies to commercialize them in highly competitive cancer segment.
Monoclonal antibodies have quite strong hold in cancer market due to high therapeutic efficacy along with minimized side effects. But, it was realized that pharmacological profiles of presently available monoclonal antibodies would not be able to offer benefits in future as cancerous cells develop resistance. Moreover, other benefits like remission, quality of life, morbidity, mortality rates and other parameters are modest at their best. Definitely, monoclonal antibodies are way superior as compared to their traditional counterparts but more improvement is required in order to offer better therapeutic effects. To overcome such issues, concept of antibody drug conjugates was developed; now this concept has been materialized due to availability of advanced technology.
For the cancer where validated predictive biomarkers are available, administration of targeted therapies such as antibody drug conjugates and others have been associated with unprecedented tumor response and clinical benefit. Efforts to design tolerable combination therapies involving antibody-drug conjugate, cancer vaccine, immune checkpoint and kinase inhibition are rational means of maximizing clinical benefit in the targeted delivery of anticancer therapies. The major advantage of using antibody drug conjugates is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the market in terms of targeted accumulation of drug in the tumor cell or tissue. Apart from this there are several other benefits of antibody drug conjugates which are driving the market and will be accelerating its share in the upcoming future.
“Global Cancer Antibody Drug Conjugates Market & Clinical Pipeline Insight 2022” report highlights:
“Global Cancer Antibody Drug Conjugates Market & Clinical Pipeline Insight 2022” report gives comprehensive insight on various clinical and non-clinical parameters involved in the development of global cancer antibody drug conjugate market. In recent years antibody drug conjugates have emerged as new growth frontier for the companies involved in the research and development of drugs for the treatment of cancer. As per report findings, currently there are 243 antibody drug conjugates in clinical pipeline for the treatment of cancer. Majority of antibody drug conjugates for the treatment of cancer are in preclinical stage followed by research phase clinical trials. There are 6 cancer antibody drug conjugates commercially available in the market. Report helps to analyze the clinical pipeline of antibody drug conjugates by Company, Indication, Mode of Action, Formulation & Phase.
Antibody drug conjugates have emerged as new addition to the cancer therapeutic segment which is already overcrowded and consists of numerous competitors. Antibody drug conjugates are based on monoclonal antibodies which delivers drugs in highly targeted manner. Their superior pharmacological profiles have allowed the pharmaceutical companies to commercialize them in highly competitive cancer segment.
Monoclonal antibodies have quite strong hold in cancer market due to high therapeutic efficacy along with minimized side effects. But, it was realized that pharmacological profiles of presently available monoclonal antibodies would not be able to offer benefits in future as cancerous cells develop resistance. Moreover, other benefits like remission, quality of life, morbidity, mortality rates and other parameters are modest at their best. Definitely, monoclonal antibodies are way superior as compared to their traditional counterparts but more improvement is required in order to offer better therapeutic effects. To overcome such issues, concept of antibody drug conjugates was developed; now this concept has been materialized due to availability of advanced technology.
For the cancer where validated predictive biomarkers are available, administration of targeted therapies such as antibody drug conjugates and others have been associated with unprecedented tumor response and clinical benefit. Efforts to design tolerable combination therapies involving antibody-drug conjugate, cancer vaccine, immune checkpoint and kinase inhibition are rational means of maximizing clinical benefit in the targeted delivery of anticancer therapies. The major advantage of using antibody drug conjugates is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the market in terms of targeted accumulation of drug in the tumor cell or tissue. Apart from this there are several other benefits of antibody drug conjugates which are driving the market and will be accelerating its share in the upcoming future.
“Global Cancer Antibody Drug Conjugates Market & Clinical Pipeline Insight 2022” report highlights:
- Impetus of Antibody Drug Conjugates
- Mechanism of Cancer Antibody Drug Conjugates
- Global Cancer Antibody Drug Conjugate Clinical Pipeline Overview
- Marketed Cancer Antibody Drug Conjugate Clinical Insight
- Global Cancer Antibody Drug Conjugate Pipeline by Company, Indication , Mode of Action, Formulation & Phase
1. IMPETUS OF ANTIBODY DRUG CONJUGATES
1.1 Prologue to Cancer Antibody Drug Conjugate
1.2 The ABCs of ADCs
2. STRUCTURAL ENTITIES OF ANTIBODY DRUG CONJUGATE
2.1 Rational Design of Antibody Drug Conjugates
2.1.1 Monoclonal Antibody
2.1.2 Linker
2.1.3 Drug Payload
2.2 Aspects of Conjugational Chemistry
3. REVOLUTIONIZING ANTIBODY DRUG CONJUGATES GENERATION
3.1 First & Second Generation ADCs
3.2 Third Generation ADCs
4. MECHANISM OF CANCER ANTIBODY DRUG CONJUGATES
4.1 Sequential Therapeutic Mechanism for Cancer
4.1.1 Selecting an Appropriate Target
4.1.2 Antigen Binding Complex
4.1.3 Antibody Drug Conjugate Internalization
4.2 Approved Antibody Drug Conjugate
5. GLOBAL CANCER ANTIBODY DRUG CONJUGATES MARKET OVERVIEW
6. GLOBAL CANCER ANTIBODY DRUG CONJUGATE CLINICAL PIPELINE OVERVIEW
6.1 Phase
6.2 Indication
6.3 Mechanism of Action
6.4 Company
6.5 Formulation
7. GLOBAL CANCER ANTIBODY DRUG CONJUGATES MARKET DYNAMICS
7.1 Favorable Market Parameters
7.2 Commercialization Challenges
8. GLOBAL CANCER ANTIBODY DRUG CONJUGATES MARKET FUTURE PROSPECTS
8.1 Approaching Newer Approaches
8.2 Upcoming Future Market Prospects
9. GLOBAL CANCER ANTIBODY DRUG CONJUGATE PIPELINE BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-II/III
9.8 Phase-III
9.9 Preregistration
10. MARKETED CANCER ANTIBODY DRUG CONJUGATE CLINICAL INSIGHT
10.1 Brentuximab Vedotin (Adcetris)
10.2 Mifamurtide (Junovan & Mepact)
10.3 Gemtuzumab Ozogamicin (Mylotarg)
10.4 Trastuzumab Emtansine (Kadcyla)
10.5 Ibritumomab Tiuxetan (Zevalin & Zevamab)
10.6 Satumomab (OncoScint CR/OV)
11. COMPETITIVE LANDSCAPE
11.1 AbbVie
11.2 AbGenomics Corporation
11.3 Biogen Idec
11.4 Biotest
11.5 Bristol-Myers Squibb
11.6 Celldex Therapeutics Inc
11.7 Helix BioPharma
11.8 IBC Pharmaceuticals
11.9 ImmunoGen
11.10 Immunomedics
11.11 Merck
11.12 Millennium
11.13 Nordic Nanovector
11.14 Novartis
11.15 PDL BioPharma
11.16 Progenics Pharmaceuticals
11.17 Roche
11.18 Seattle Genetics
11.19 Stem CentRx
11.20 UCB
11.21 Viventia Biotechnologies
1.1 Prologue to Cancer Antibody Drug Conjugate
1.2 The ABCs of ADCs
2. STRUCTURAL ENTITIES OF ANTIBODY DRUG CONJUGATE
2.1 Rational Design of Antibody Drug Conjugates
2.1.1 Monoclonal Antibody
2.1.2 Linker
2.1.3 Drug Payload
2.2 Aspects of Conjugational Chemistry
3. REVOLUTIONIZING ANTIBODY DRUG CONJUGATES GENERATION
3.1 First & Second Generation ADCs
3.2 Third Generation ADCs
4. MECHANISM OF CANCER ANTIBODY DRUG CONJUGATES
4.1 Sequential Therapeutic Mechanism for Cancer
4.1.1 Selecting an Appropriate Target
4.1.2 Antigen Binding Complex
4.1.3 Antibody Drug Conjugate Internalization
4.2 Approved Antibody Drug Conjugate
5. GLOBAL CANCER ANTIBODY DRUG CONJUGATES MARKET OVERVIEW
6. GLOBAL CANCER ANTIBODY DRUG CONJUGATE CLINICAL PIPELINE OVERVIEW
6.1 Phase
6.2 Indication
6.3 Mechanism of Action
6.4 Company
6.5 Formulation
7. GLOBAL CANCER ANTIBODY DRUG CONJUGATES MARKET DYNAMICS
7.1 Favorable Market Parameters
7.2 Commercialization Challenges
8. GLOBAL CANCER ANTIBODY DRUG CONJUGATES MARKET FUTURE PROSPECTS
8.1 Approaching Newer Approaches
8.2 Upcoming Future Market Prospects
9. GLOBAL CANCER ANTIBODY DRUG CONJUGATE PIPELINE BY COMPANY, INDICATION & PHASE
9.1 Research
9.2 Preclinical
9.3 Clinical
9.4 Phase-I
9.5 Phase-I/II
9.6 Phase-II
9.7 Phase-II/III
9.8 Phase-III
9.9 Preregistration
10. MARKETED CANCER ANTIBODY DRUG CONJUGATE CLINICAL INSIGHT
10.1 Brentuximab Vedotin (Adcetris)
10.2 Mifamurtide (Junovan & Mepact)
10.3 Gemtuzumab Ozogamicin (Mylotarg)
10.4 Trastuzumab Emtansine (Kadcyla)
10.5 Ibritumomab Tiuxetan (Zevalin & Zevamab)
10.6 Satumomab (OncoScint CR/OV)
11. COMPETITIVE LANDSCAPE
11.1 AbbVie
11.2 AbGenomics Corporation
11.3 Biogen Idec
11.4 Biotest
11.5 Bristol-Myers Squibb
11.6 Celldex Therapeutics Inc
11.7 Helix BioPharma
11.8 IBC Pharmaceuticals
11.9 ImmunoGen
11.10 Immunomedics
11.11 Merck
11.12 Millennium
11.13 Nordic Nanovector
11.14 Novartis
11.15 PDL BioPharma
11.16 Progenics Pharmaceuticals
11.17 Roche
11.18 Seattle Genetics
11.19 Stem CentRx
11.20 UCB
11.21 Viventia Biotechnologies
LIST OF FIGURES
Figure 1-1: Advantages of Antibody Drug Conjugates
Figure 2-1: Detailed Structure of Antibody Drug Conjugate
Figure 2-2: Components of Antibody Drug Conjugates
Figure 2-3: Categorization of the Types of Linkers
Figure 2-4: Conjugation Strategies Adopted for Antibody Drug Conjugate
Figure 3-1: Difference Between First & Second Generation Antibody Drug Conjugate
Figure 3-2: Major Challenges of the Second Generation Antibody Drug Conjugate
Figure 4-1: Mechanism of Antibody Drug Conjugate
Figure 4-2: Mechanism of Brentuximab Vedotin
Figure 4-3: Mechanism of Trastuzumab Emtansine
Figure 5-1: Global - Antibody Drug Conjugates Market (US$ Billion), 2014-2022
Figure 5-2:Global - Adcetris Sales (Million US$), 2016-2022
Figure 5-3: Global - Kadcyla Sales (Million US$), 2016-2022
Figure 5-4: Global - Kadcyla Sales by Region (%), 2016
Figure 6-1: Global - Cancer Antibody Drug Conjugates Pipeline By Phase (%), 2017 till 2022
Figure 6-2: Global - Cancer Antibody Drug Conjugates Pipeline By Phase (Number), 2017 till 2022
Figure 6-3: Global - Cancer Antibody Drug Conjugates Pipeline By Indication (Number), 2017 till 2022
Figure 6-4: Global - Cancer Antibody Drug Conjugates Pipeline By Mode of Action (Number), 2017 till 2022
Figure 6-5: Global - Cancer Antibody Drug Conjugates Pipeline By Company (Number), 2017 till 2022
Figure 6-6: Global - Cancer Antibody Drug Conjugates Pipeline By Formulation (Number), 2017 till 2022
Figure 7-1: Antibody Drug Conjugates Market Favorable Parameters
Figure 7-2: Major Challenges Faced by Antibody Drug Conjugate Market
Figure 11-1:AbGenomics - Clinical Pipeline
Figure 11-2: Celldex - Clinical Pipeline
Figure 11-3: Merck - Clinical Pipeline
Figure 11-4: Millennium - Clinical Pipeline
Figure 11-5: Novartis - Clinical Pipeline
Figure 11-6: Progenics - Clinical Pipeline
Figure 11-7: Roche - Clinical Pipeline
Figure 11-8: Seattle Genetics - Clinical Pipeline
Figure 11-9: Viventia - Clinical Pipepline
Figure 1-1: Advantages of Antibody Drug Conjugates
Figure 2-1: Detailed Structure of Antibody Drug Conjugate
Figure 2-2: Components of Antibody Drug Conjugates
Figure 2-3: Categorization of the Types of Linkers
Figure 2-4: Conjugation Strategies Adopted for Antibody Drug Conjugate
Figure 3-1: Difference Between First & Second Generation Antibody Drug Conjugate
Figure 3-2: Major Challenges of the Second Generation Antibody Drug Conjugate
Figure 4-1: Mechanism of Antibody Drug Conjugate
Figure 4-2: Mechanism of Brentuximab Vedotin
Figure 4-3: Mechanism of Trastuzumab Emtansine
Figure 5-1: Global - Antibody Drug Conjugates Market (US$ Billion), 2014-2022
Figure 5-2:Global - Adcetris Sales (Million US$), 2016-2022
Figure 5-3: Global - Kadcyla Sales (Million US$), 2016-2022
Figure 5-4: Global - Kadcyla Sales by Region (%), 2016
Figure 6-1: Global - Cancer Antibody Drug Conjugates Pipeline By Phase (%), 2017 till 2022
Figure 6-2: Global - Cancer Antibody Drug Conjugates Pipeline By Phase (Number), 2017 till 2022
Figure 6-3: Global - Cancer Antibody Drug Conjugates Pipeline By Indication (Number), 2017 till 2022
Figure 6-4: Global - Cancer Antibody Drug Conjugates Pipeline By Mode of Action (Number), 2017 till 2022
Figure 6-5: Global - Cancer Antibody Drug Conjugates Pipeline By Company (Number), 2017 till 2022
Figure 6-6: Global - Cancer Antibody Drug Conjugates Pipeline By Formulation (Number), 2017 till 2022
Figure 7-1: Antibody Drug Conjugates Market Favorable Parameters
Figure 7-2: Major Challenges Faced by Antibody Drug Conjugate Market
Figure 11-1:AbGenomics - Clinical Pipeline
Figure 11-2: Celldex - Clinical Pipeline
Figure 11-3: Merck - Clinical Pipeline
Figure 11-4: Millennium - Clinical Pipeline
Figure 11-5: Novartis - Clinical Pipeline
Figure 11-6: Progenics - Clinical Pipeline
Figure 11-7: Roche - Clinical Pipeline
Figure 11-8: Seattle Genetics - Clinical Pipeline
Figure 11-9: Viventia - Clinical Pipepline
LIST OF TABLES
Table 4-1: FDA Approved Antibody Drug Conjugate For Cancer
Table 4-2: Some of the Antibody Drug Conjugates under Development
Table 5-1: Drugs for Treatment of HER2-Positive Breast Cancer
COMPANIES
AbbVie, AbGenomics Corporation, Biogen Idec, Biotest, Bristol-Myers Squibb, Celldex Therapeutics Inc, Helix BioPharma, IBC Pharmaceuticals, ImmunoGen, Immunomedics, Merck, Millennium, Nordic Nanovector, Novartis, PDL BioPharma, Progenics Pharmaceuticals, Roche, Seattle Genetics, Stem CentRx, UCB, Viventia Biotechnologies
Table 4-1: FDA Approved Antibody Drug Conjugate For Cancer
Table 4-2: Some of the Antibody Drug Conjugates under Development
Table 5-1: Drugs for Treatment of HER2-Positive Breast Cancer
COMPANIES
AbbVie, AbGenomics Corporation, Biogen Idec, Biotest, Bristol-Myers Squibb, Celldex Therapeutics Inc, Helix BioPharma, IBC Pharmaceuticals, ImmunoGen, Immunomedics, Merck, Millennium, Nordic Nanovector, Novartis, PDL BioPharma, Progenics Pharmaceuticals, Roche, Seattle Genetics, Stem CentRx, UCB, Viventia Biotechnologies
